仅用于工业应用或科学研究，不可用于人类或动物的临床诊断或治疗，非药用. Mirzotamab is an IgG1κ antibody targeting to CD276/B7-H3. Mirzotamab can conjugates with Clezutoclax （HY-137774）, an BCL inhibitor to form Mirzotamab clezutoclax （HY-P99741）, involving in research with taxane research in relapsed/refractory solid tumors. Mirzotamab clezutoclax （ABBV-155） is a targeted antibody drug conjugate （ADC）